Search | Clinical Trials Finder

Conditions: Gastric Adenocarcinoma, Esophageal Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma
Interventions: RP2, 5-Fluorouracil, Leucovorin, Oxaliplatin, Docetaxel, Pegfilgrastim, Filgrastim, Surgical Resection of Primary Tumor; Biological · Combination Product · Drug + 1 more
Lead sponsor: Abramson Cancer Center at Penn Medicine; Other
Eligibility: 18 Years and older
Enrollment: 34 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Gastric Neoplasms, Esophageal Cancer, Liver Cancer, Liver Metastasis, MSS-CRC, MSS, Gastric Adenocarcinoma, Peritoneal Cancer, Peritoneal Carcinoma, Peritoneal Metastases, MSI-H, Gastric Cancer
Interventions: vvDD-hIL-2-RG-1; Biological
Lead sponsor: Allegheny Singer Research Institute (also known as Allegheny Health Network Research Institute); Other
Eligibility: 18 Years to 69 Years
Enrollment: 18 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Anal Cancer, Colorectal Cancer, Esophageal Cancer, Extrahepatic Bile Duct Cancer, Gallbladder Cancer, Gastric Cancer, Head and Neck Cancer, Liver Cancer, Lung Cancer, Pancreatic Cancer, Small Intestine Cancer
Interventions: Not listed
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years to 120 Years
Enrollment: 144 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2015
U.S. locations: 1
States / cities: Scottsdale, Arizona

Conditions: Adenocarcinoma of the Gastroesophageal Junction, Esophageal Undifferentiated Carcinoma, Gastric Adenocarcinoma, Gastric Squamous Cell Carcinoma, Recurrent Esophageal Adenocarcinoma, Recurrent Esophageal Squamous Cell Carcinoma, Recurrent Gastric Carcinoma, Stage IIIB Esophageal Adenocarcinoma, Stage IIIB Esophageal Squamous Cell Carcinoma, Stage IIIB Gastric Cancer, Stage IIIC Esophageal Adenocarcinoma, Stage IIIC Esophageal Squamous Cell Carcinoma, Stage IIIC Gastric Cancer, Stage IV Esophageal Adenocarcinoma, Stage IV Esophageal Squamous Cell Carcinoma, Stage IV Gastric Cancer, Undifferentiated Gastric Carcinoma
Interventions: Laboratory Biomarker Analysis, Oxaliplatin, Pralatrexate; Other · Drug
Lead sponsor: Roswell Park Cancer Institute; Other
Eligibility: 18 Years and older
Enrollment: 35 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2015
U.S. locations: 2
States / cities: Buffalo, New York • Rochester, New York

Conditions: Gastric Cancer
Interventions: Rilotumumab, Placebo, Epirubicin, Cisplatin, Capecitabine; Drug · Other
Lead sponsor: Amgen; Industry
Eligibility: 18 Years to 99 Years
Enrollment: 609 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2015
U.S. locations: 16
States / cities: Tucson, Arizona • Aurora, Colorado • Pueblo, Colorado + 13 more

Conditions: Esophageal Cancer
Interventions: cisplatin, gefitinib, irinotecan hydrochloride, conventional surgery, neoadjuvant therapy, radiation therapy; Drug · Procedure · Radiation
Lead sponsor: University of California, San Francisco; Other
Eligibility: 18 Years and older
Enrollment: 6 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2008
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Gastric Cancer, Esophageal Adenocarcinoma, Hepatocellular Carcinoma, Colorectal Cancer
Interventions: Cabozantinib, Durvalumab, Tremelimumab; Drug
Lead sponsor: Anwaar Saeed; Other
Eligibility: 18 Years and older
Enrollment: 117 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2029
U.S. locations: 2
States / cities: Westwood, Kansas • Pittsburgh, Pennsylvania

Conditions: Solid Tumors
Interventions: Regorafenib, (Stivarga, BAY73-4506), Nivolumab (Opdivo); Drug
Lead sponsor: Bayer; Industry
Eligibility: 18 Years and older
Enrollment: 175 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2024
U.S. locations: 6
States / cities: Duarte, California • Aurora, Colorado • Tampa, Florida + 3 more

Conditions: Esophageal Cancer
Interventions: cisplatin, docetaxel, irinotecan hydrochloride, radiation therapy; Drug · Radiation
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 27 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2009
U.S. locations: 1
States / cities: New York, New York

Conditions: Gastric Cancer, Esophageal Neoplasms
Interventions: irinotecan, docetaxel; Drug
Lead sponsor: University of Southern California; Other
Eligibility: 18 Years and older
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2015
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Pancreatic Cancer, Breast Cancer, Gastric Cancer, Non Small Cell Lung Cancer, Cervical Cancer, Endocervical Cancer, Squamous Cell Carcinoma of Head and Neck, Bladder Urothelial Cancer, Colorectal Cancer, Esophageal Cancer, Ovarian Cancer, Renal Cell Carcinoma, Prostate Cancer, Melanoma, Mesothelioma, Cholangiocarcinoma
Interventions: NGM438, Pembrolizumab (KEYTRUDA ®); Drug
Lead sponsor: NGM Biopharmaceuticals, Inc; Industry
Eligibility: 18 Years and older
Enrollment: 71 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2025
U.S. locations: 6
States / cities: Denver, Colorado • New Haven, Connecticut • Detroit, Michigan + 3 more

Conditions: Esophageal Cancer
Interventions: paclitaxel; Drug
Lead sponsor: Theradex; Industry
Eligibility: 18 Years and older
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 1997
U.S. locations: 30
States / cities: Mobile, Alabama • Loma Linda, California • San Francisco, California + 25 more

Conditions: Barrett's Esophagus, Esophageal Adenocarcinoma
Interventions: EMR and RFA effect on stem cell marker expression in BE/EAC; Other
Lead sponsor: University of Oklahoma; Other
Eligibility: 18 Years to 85 Years
Enrollment: 32 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2019
U.S. locations: 1
States / cities: Oklahoma City, Oklahoma

Conditions: Gastrointestinal Cancer, Colorectal Cancer, Pancreatic Adenocarcinoma, Gastric Cancer, Esophageal Cancer, Cholangiocarcinoma, Hepatocellular Carcinoma, Neuroendocrine Tumors, GIST, Malignant
Interventions: Serious Illness Conversation Guide (SICG), Quality of Life (QOL) survey; Behavioral
Lead sponsor: Stanford University; Other
Eligibility: Not listed
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2020
U.S. locations: 1
States / cities: Stanford, California

Conditions: Muscle Invasive Bladder Urothelial Carcinoma, Esophageal Cancer, Gastric and Gastroesophageal Junction (GEJ) Adenocarcinoma, Melanoma (Skin Cancer), NSCLC (Non-small Cell Lung Cancer), Pancreatic (Exocrine Only), Mix of Solid Tumors (MOST)
Interventions: blood and tissue samples, blood and tissue samples; Diagnostic Test · Other
Lead sponsor: Paradigm Health; Industry
Eligibility: 18 Years and older
Enrollment: 1,350 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2032
U.S. locations: 2
States / cities: San Diego, California • Maumee, Ohio

Conditions: Esophageal Cancer, Squamous Cell Esophagus Cancer, Adenocarcinoma Esophagus
Interventions: Pembrolizumab; Drug
Lead sponsor: Dana-Farber Cancer Institute; Other
Eligibility: 18 Years and older
Enrollment: 49 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2020
U.S. locations: 3
States / cities: Boston, Massachusetts

Conditions: Cervical Cancer, Microsatellite Instability (MSI)-High Endometrial Cancer, Gastric Cancer (Including Stomach and Gastroesophageal Junction [GEJ]), Esophageal Cancer, Hepatocellular Carcinoma, Melanoma (Uveal Melanoma Excluded), Merkel Cell Carcinoma, Mesothelioma, MSI-high Colorectal Cancer, Non-small Cell Lung Cancer (NSCLC), Ovarian Cancer, Squamous Cell Carcinoma of the Head and Neck (SCCHN), Small Cell Lung Cancer (SCLC), Renal Cell Carcinoma (RCC), Triple-negative Breast Cancer, Urothelial Carcinoma, Diffuse Large B-cell Lymphoma
Interventions: INCAGN02385; Biological
Lead sponsor: Incyte Biosciences International Sàrl; Industry
Eligibility: 18 Years and older
Enrollment: 22 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2020
U.S. locations: 4
States / cities: Los Angeles, California • Hackensack, New Jersey • Huntersville, North Carolina + 1 more

Conditions: Adenocarcinoma of the Gastroesophageal Junction, Esophageal Cancer
Interventions: panitumumab, cisplatin, docetaxel, neoadjuvant therapy, therapeutic conventional surgery, radiation therapy; Biological · Drug · Procedure + 1 more
Lead sponsor: Alliance for Clinical Trials in Oncology; Other
Eligibility: 18 Years and older
Enrollment: 70 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2014
U.S. locations: 21
States / cities: Savannah, Georgia • Chicago, Illinois • Evanston, Illinois + 15 more

Conditions: Clinical Stage III Gastric Cancer AJCC v8, Clinical Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8, Clinical Stage IV Gastric Cancer AJCC v8, Clinical Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8, Metastatic Gastric Adenocarcinoma, Metastatic Gastroesophageal Junction Adenocarcinoma, Unresectable Gastric Adenocarcinoma, Unresectable Gastroesophageal Junction Adenocarcinoma
Interventions: Berzosertib, Computed Tomography Assisted Biopsy, Endoscopic Biopsy, Irinotecan, Magnetic Resonance Imaging; Drug · Procedure
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 17 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2027
U.S. locations: 31
States / cities: Duarte, California • Los Angeles, California • Orange, California + 25 more

Conditions: Esophageal Cancer
Interventions: VLE imaging for staging EAC; Diagnostic Test
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years to 95 Years
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2021
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Head and Neck Squamous Cell Carcinoma HNSCC, Non-Small Cell Lung Cancer NSCLC, Esophageal Cancer, Gastric Cancer, Colorectal Cancer, Pancreatic Ductal Adenocarcinoma (PDAC), Cervical Cancer, Endometrial Cancer, Urothelial Cancer
Interventions: STRO-004, Pembrolizumab; Drug
Lead sponsor: Sutro Biopharma, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 6
States / cities: Denver, Colorado • Sarasota, Florida • Boston, Massachusetts + 3 more

Conditions: Advanced Lymphoma, Advanced Malignant Solid Neoplasm, Bladder Carcinoma, Breast Carcinoma, Cervical Carcinoma, Colon Carcinoma, Colorectal Carcinoma, Endometrial Carcinoma, Esophageal Carcinoma, Exocrine Pancreas Carcinoma, Gastric Carcinoma, Glioma, Head and Neck Carcinoma, Hematopoietic and Lymphoid Cell Neoplasm, Kidney Carcinoma, Liver Carcinoma, Lung Carcinoma, Lymphoma, Malignant Uterine Corpus Neoplasm, Malignant Uterine Neoplasm, Melanoma, Multiple Myeloma, Ovarian Carcinoma, Prostate Carcinoma, Rectal Carcinoma, Recurrent Bladder Carcinoma, Recurrent Breast Carcinoma, Recurrent Cervical Carcinoma, Recurrent Colon Carcinoma, Recurrent Colorectal Carcinoma, Recurrent Esophageal Carcinoma, Recurrent Gastric Carcinoma, Recurrent Glioma, Recurrent Head and Neck Carcinoma, Recurrent Liver Carcinoma, Recurrent Lung Carcinoma, Recurrent Lymphoma, Recurrent Malignant Solid Neoplasm, Recurrent Malignant Uterine Corpus Neoplasm, Recurrent Melanoma, Recurrent Multiple Myeloma, Recurrent Ovarian Carcinoma, Recurrent Pancreatic Carcinoma, Recurrent Prostate Carcinoma, Recurrent Rectal Carcinoma, Recurrent Skin Carcinoma, Recurrent Thyroid Gland Carcinoma, Refractory Lymphoma, Refractory Malignant Solid Neoplasm, Refractory Multiple Myeloma, Skin Carcinoma, Thyroid Gland Carcinoma
Interventions: Adavosertib, Afatinib, Afatinib Dimaleate, Binimetinib, Biopsy Procedure, Biospecimen Collection, Capivasertib, Computed Tomography, Copanlisib, Copanlisib Hydrochloride, Crizotinib, Cytology Specimen Collection Procedure, Dabrafenib, Dabrafenib Mesylate, Dasatinib, Defactinib, Defactinib Hydrochloride, Echocardiography Test, Erdafitinib, Fexagratinib, Ipatasertib, Laboratory Biomarker Analysis, Larotrectinib, Larotrectinib Sulfate, Magnetic Resonance Imaging, Multigated Acquisition Scan, Nivolumab, Osimertinib, Palbociclib, Pertuzumab, PI3K-beta Inhibitor GSK2636771, Radiologic Examination, Radionuclide Imaging, Relatlimab, Sapanisertib, Sunitinib Malate, Taselisib, Trametinib, Trastuzumab, Trastuzumab Emtansine, Ulixertinib, Vismodegib; Drug · Procedure · Other + 1 more
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 6,452 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2026
U.S. locations: 1407
States / cities: Birmingham, Alabama • Fairhope, Alabama • Mobile, Alabama + 848 more

Conditions: Metastatic Esophageal Adenocarcinoma, Metastatic Esophageal Squamous Cell Carcinoma, Metastatic Gastroesophageal Junction Adenocarcinoma, Recurrent Esophageal Adenocarcinoma, Recurrent Esophageal Carcinoma, Recurrent Esophageal Squamous Cell Carcinoma, Recurrent Gastroesophageal Junction Adenocarcinoma, Stage IV Esophageal Cancer AJCC v7
Interventions: Cixutumumab, Laboratory Biomarker Analysis, Paclitaxel, Pharmacological Study; Biological · Other · Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 94 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2027
U.S. locations: 233
States / cities: Scottsdale, Arizona • Palo Alto, California • Aurora, Colorado + 173 more

Conditions: Esophageal Cancer, Esophageal Adenocarcinoma, Esophageal Squamous Cell Cancer, Esophageal Neoplasms, Squamous Cell Carcinoma
Interventions: Chemoradiotherapy, Esophagectomy; Other · Procedure
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years to 99 Years
Enrollment: 2 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2018
U.S. locations: 1
States / cities: Bethesda, Maryland

Search by objective public record fields.

Neoadjuvant Intra-tumoral RP2 and FLOT in Gastroesophageal Adenocarcinoma

Intra-tumoral (IT) Injection of vvDD-hIL2-2-RG-1 for Metastatic Gastrointestinal and Peritoneal Tumors

Quality of Life in Patients Undergoing Radiation Therapy for Primary Lung Cancer, Head and Neck Cancer, or Gastrointestinal Cancer

Pralatrexate and Oxaliplatin in Treating Patients With Unresectable or Metastatic Esophageal, Stomach, or Gastroesophageal Junction Cancer

First-Line Treatment for Locally Advanced or Metastatic Mesenchymal Epithelial Transition Factor (MET) - Positive Gastric, Lower Esophageal, or Gastroesophageal Junction (GEJ) Adenocarcinoma

Gefitinib, Cisplatin, Irinotecan, and Radiation Therapy Before Surgery in Treating Patients With Esophageal Cancer or Gastroesophageal Junction Cancer That Can Be Removed By Surgery

Cabozantinib Plus Durvalumab With or Without Tremelimumab in Patients With Gastroesophageal Cancer and Other Gastrointestinal Malignancies

A Trial to Learn Whether Regorafenib in Combination With Nivolumab Can Improve Tumor Responses and How Safe it is for Participants With Solid Tumors

Irinotecan, Radiation Therapy, and Docetaxel With or Without Cisplatin in Treating Patients With Locally Advanced Esophageal Cancer

Study of Irinotecan and Docetaxel in Patients With Metastatic or Unresectable Gastric or Gastroesophageal Junction Adenocarcinoma

Study of NGM438 as Monotherapy and in Combination With Pembrolizumab in Advanced or Metastatic Solid Tumors

Paclitaxel in Treating Patients With Metastatic, Recurrent, or Unresectable Cancer of the Esophagus

DCLK1 as a Marker/Indicator of Stem Cell Response in Barrett's Esophagus/Esophageal Adenocarcinoma

Assessment of a Serious Illness Conversation Guide (SICG) in Advanced Gastro-Intestinal Cancers

Pan-tumor MRD Study

Pembrolizumab in Refractory Advanced Esophageal Cancer

A Safety and Tolerability Study of INCAGN02385 in Select Advanced Malignancies

Panitumumab, Docetaxel, Cisplatin, Radiation Therapy, and Surgery in Treating Patients With Newly Diagnosed, Locally Advanced Esophageal Cancer or Cancer of the Gastroesophageal Junction

Berzosertib and Irinotecan in Treating Patients With Progressive, Metastatic, or Unresectable TP53 Mutant Gastric or Gastroesophageal Junction Cancer

Staging of Superficial EAC Using VLE

A Study of STRO-004 in Adults With Refractory/Recurrent Metastatic Cancer

Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)

Paclitaxel With or Without Cixutumumab as Second-Line Therapy in Treating Patients With Metastatic Esophageal Cancer or Gastroesophageal Junction Cancer

Metabolomic and BH3 Profiling of Esophageal Cancers: Identification of Novel Assessment Methods of Treatment Response for Precision Therapy